Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries
Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries
复制标题
DOI：
10.1093/jncimonographs/lgz033
复制
发表时间：
2020-05-01
期刊：
影响因子：
--
通讯作者：
Mariotto, Angela B.
中科院分区：
文献类型：
--
作者：
Lam, Clara J. K.;Warren, Joan L.;Mariotto, Angela B.
越来越多的使用口服系统治疗和一些癌症治疗过渡到门诊设置使得捕获所有癌症病例患者更加困难。我们的目标是开发算法来识别潜在的漏诊病例患者，并估计对发病率的影响。我们回顾了来自SEER-Medicare 5%非癌症对照患者样本的索赔，以根据诊断代码、癌症相关治疗和肿瘤学咨询确定潜在遗漏的慢性髓性白血病（CML）和膀胱病例患者。计算CML确诊漏诊率、膀胱确诊漏诊率及可能漏诊率，评估两种肿瘤的漏诊率对SEER 65+发生率的影响。从2008年到2015年，该算法估计遗漏了781例明确的CML病例，增加了10.7%。从2007年到2015年，该算法估计漏诊的确诊膀胱病例4629例，疑似膀胱病例5772例，增加了3.8%至8.1%。我们的算法为识别漏诊患者和验证癌症登记的完整性提供了潜在的方法。
The growing use of oral systemic therapies and transition of some cancer treatments to the outpatient setting makes capturing all cancer case patients more difficult. We aim to develop algorithms to identify potentially missed incident case patients and estimate impact on incidence rates. We reviewed claims from SEER-Medicare 5% noncancer control patient sample to identify potentially missed chronic myeloid leukemia (CML) and bladder case patients based on diagnosis codes, cancer-related treatments, and oncology consultations. Observed rates of definite missed CML and definite and probable missed bladder case patients were calculated and the impact of missed case patients of these two cancers on SEER 65+ incidence rates were estimated. From 2008 to 2015, the algorithm estimated 781 definite CML case patients missed, increasing the number by 10.7%. From 2007 to 2015, the algorithm estimated 4629 definite and 5772 probable bladder case patients missed, increasing the number by 3.8% to 8.1%. Our algorithms offer potential methods for identifying missed case patients and validating the completeness of cancer registries.